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Congenital Plasminogen Deficiency Caused by a SerS7* to Pro Mutation
By Hiroyuki Azuma, Yuka Uno, Toshio Shigekiyo, and Shiro Saito
We used a polymerase chain reaction (PCR) strategy and restriction fragment polymorphism analysis to evaluate all 19 exons of the plasminogen (PLG) gene in a Japanese patient with congenital PLG deficiency and her family members. She presented with cerebral infarction. Sequence analysis following amplification of each exon and its flanking regions showed a single T to C transition in exon 14, which changed a Se?72 codon (TCC) to Pro5" codon (CCC). Since this mutation generates a new Fok I site, the Fok I digestion pattern of the PCR-amplified exon
HROMBOTIC EVENTS associated with quantitative
T and qualitative abnormalities of plasma coagulation and fibrinolytic factors such as antithrombin (AT)III, protein C, protein s, heparin cofactor (HC) 11, and plasminogen (PLG) have been described since the first family of congenital ATIII deficiency manifesting venous thrombosis was reported in 1965 by Egeberg.'.' It is reported that approximately 15% of venous thrombosis that presents at a relatively younger age or is recurrent with no other explanation can be associated with genetic defects of these plasma factors.' A close relationship between thrombosis and atherosclerosis also has been postulated; namely, thrombus formation provokes endothelial cell injury, which results in the progression of atherosclerotic lesions. Atherosclerosis can also accelerate thrombus f~r m a t i o n .~.~ Thus, the identification and detection of genetic defects in plasma factors responsible for vascular thrombosis is important for affected individuals and their family members, not only in terms of preventing thrombosis, but also of reducing the formation and progression of atherosclerotic lesions.
PLG is the proenzyme of the serine protease plasmin and is a 79 1 -amino acid residue single chain glycoprotein with a molecular weight of 93 Kd.5 Its gene spans approximately 52.5 kb on chromosome 6q26-27 and consists of 19 exons.' Cleavage at the Arg56'-Va1562 bond on PLG by tissue PLG activator (tPA) or urokinase results in the formation of plasmin, which consists of a heavy chain (kringle domain) and a light chain (serine protease domain), held together by two disulfide bonds6 The proteolytic activity of plasmin contributes to the digestion of the insoluble fibrin clot and thrombi by which normal recanalization and tissue repair can be accomplished. Therefore, the reduction in plasma plasmin levels by PLG deficiency would disrupt these normal processes and may result in a thrombotic tendency. Indeed, approximately 20 patients with PLG deficiency manifesting vascular thrombosis have been reported to date, although the mutations responsible for the deficiency in these patients have not yet been determir~ed.~. ' In this study, we identified the precise genetic abnormality in a Japanese family with PLG deficiency.
MATERIALS AND METHODS

Materials.
All restriction enzymes, T4 DNA ligase, and M I3mp19 RF DNA were purchased from Toyobo (Osaka, Japan). X-gal and IPTG were obtained from Takara Shuzo (Osaka, Japan).
The Sequenase Version 2 Deaza-dCTP kit was purchased from US 14 fragments from each family member was analyzed. In all cases, the patterns were consistent with the activities and antigen levels of plasma PLG in those members. Furthermore, all PCR-amplified exon 1 4 fragments from l 5 normal individuals were not restricted with Fok I endonuclease. We conclude that a T to C transition in exon 1 4 identified in the propositus is responsible for PLG deficiency inherited in this Japanese family with thrombotic episodes.
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Biochemical (Cleveland, OH). Taq DNA polymerase (Amplitaq) was obtained from Perkin Elmer-Cetus (Nonvalk, CT). An ultrapure dNTP set was purchased from Pharmacia LKB Biotechnology (Uppsala, Sweden). Escherichia coli strain XL1-Blue was purchased from Stratagene (La Jolla, CA). The Geneclean I1 kit was obtained from Bio 101 (La Jolla, CA). Tetracycline and ethidium bromide were purchased from Sigma Chemical (St Louis, MO). Agarose (SeaKem HGT) was purchased from FMC (Rockland, ME Clinical characteristics of the subjects. The relevant clinical and laboratory data of family N with congenital PLG deficiency studied in this report have been previously described.' In brief, the propositus (111-2 in Fig 2B) is a 43-year-old Japanese woman with a late onset epilepsy as a result of a cerebral infarction. The levels of various plasma factors that are associated with hereditary thrombosis, ie, ATIII, protein C, protein S, HCII, histidine-rich glycoprotein, tPA, and PLG activator inhibitor-1, were all within the normal range, except for a parallel decrease in both the activity and antigen level of PLG to 54% (normal, 80% to 110%) and 4.8 mg/dL (normal, 9.8 to 14.6 mg/dL), respectively. Among her family members, the activity and antigen levels of PLG in her 63-year-old mother (11-2 in Fig 2B) , who had had an episode of arterial thrombosis of the left femur at the age of 56, were 68% and 6.9 mg/dL, respectively, and those of her daughter (IV-3 in Fig 2B) were 62% and 5.8 mg/dL, respectively. The propositus' husband (11-4 in Fig 2B) was a cousin of her mother. These data demonstrated that PLG deficiency observed in family N segregated through at least three generations, and that the propositus, her mother, and her daughter were heterozygous for PLG deficiency.
DNA isolation and Southern blot analysis. Blood was drawn from all individuals after obtaining informed consent according to the Declaration of Helsinki and following the institutional guidelines of the University of Tokushima. Genomic DNA was isolated from whole blood as described previously.8 A plasmid containing the entire cDNA sequence of human PLG, pPLGKG, kindly provided by Dr Forsgren (University of Lund, S~e d e n ) ,~ was digested with HindIII (this site is in the pBS322 vector, approximately 150 bp upstream of the initiation codon of the PLG cDNA) and Sph I (62 bp downstream of the termination codon of the PLG cDNA). An approximately 2.7-kb HindIII/Sph I fragment was isolated using Geneclean for Southern blot analysis described below. Ten micrograms ofgenomic DNA was digested with either EcoRI, BamHI, Xba I, Msp I, or Sac I, and subsequently separated by electrophoresis through a 0.7% agarose gel. The DNA was transferred to a Hybond-N membrane and hybridized with the 32P-labeled 2.7-kb HindIII/Sph I fragment according to a standard procedure." The hybridized membrane was exposed to Kodak X-Omat AR films (Eastman Kodak, Rochester, NY) at -80°C with an intensifying screen.
Polymerase chain reaction (PCR) amplijication and DNA sequence analysis. Oligonucleotide primers for PCR were synthesized by a DNA synthesizer (model 38 1 A, Applied Biosystems, Foster City, CA) based on the published genomic DNA sequence of human PLG5 Each exon, including the exon-intron boundary, was amplified with a set of oligonucleotide primers listed in Table 1 . The PCR reaction mixture contained 1 x PCR buffer (10 mmol/L Tris/HCl, pH 8.4, 50 mmol/L KCl, 1.5 mmol/L MgCI,, 0.01% gelatin), 1 pg of both upstream and downstream primers, 2 mmol/L each dNTP, 1 pg of genomic DNA, and 2 U of Taq polymerase. Denaturation, annealing, and extension reactions were performed at 94°C for 1 minute, at 55°C for 1 minute, and at 72°C for 1.5 minutes, respectively, and the amplification was continued for 35 cycles. Unique restriction sites, EcoRI or BamHI, were incorporated within the 5' end of each oligonucleotide primer to facilitate the subsequent subcloning into M 13mp19, which was digested previously with EcoRI/BamHI. Because the coding sequence ofexon 2 contained an EcoRI site, an Xba I site was added onto the 5' end of its upstream-oligonucleotide primer. This amplified fragment was then subcloned into the Xba IIBamH1 site of M13mp19. The single-stranded DNA containing the human PLG DNA was sequenced using dideoxy chain-termination reactions with T7 DNA polymerase and [(u-~~SI~CTP. Digestion of the PCR fragments with the restriction enzyme Fok I was performed using the manufacturer's recommended conditions. Fifteen normal individuals were studied to analyze the presence of the Fok I site.
RESULTS
To investigate any gross structural alterations in the PLG gene of the propositus, genomic DNA, digested with EcoRI, BamHI, Xba I, Msp I, and Sac I, was subjected to Southern blot analysis. The digestion pattern of the propositus was indistinguishable from those of normal individuals, suggesting that no gross deletion or insertion occurred in the PLG gene of the propositus (data not shown). This result suggested that there was a small deletion or point mutation(s) in the gene, and we used a strategy based on the PCR technique to detect it. We first assumed that the phenotype would be caused by a nonsense mutation within the gene, although a truncated gene product was not detected in patient's plasma. Since the CpG dinucleotide is generally recognized as a "hotspot" for a C to T transition mutation and can create a nonsense codon at an Arg codon (CGA)," we amplified exons 10, 12, and 16, because in each exon one CpG dinucleotide is present. These amplified fragments were sequenced using M 13
Genetic basis of the PLG deficiency.
single-stranded templates, but no mutation was detected. Subsequently, all of the remaining exons were individually amplified and subjected to DNA sequence analysis. As shown in Fig I , a single T to C transition, which changed the Ser572 codon (TCC) in exon 14 to a codon (CCC), was identified in four of 10 different clones selected. Other clones from the same propositus contained the normal Ser572 codon, indicating that the propositus was heterozygous for the observed amino acid change, a finding consistent with the autosomal dominant mode of inheritance seen in this family. No base changes were detected in the exonintron junctions and the GT-AG donorfacceptor sequences were conserved at each splice junction.
In the process of sequencing all of the exons in the PLG gene, several additional conclusions were derived from the sequence data. First, when exon 16 was amplified and sequenced, 15 of 29 selected clones had a normal PLG sequence, while the remaining 14 clones had a sequence identical to the apo(a) gene, except that there was an A to G substitution at nucleotide 13242 (numbering according to McLean et al") which results in an lle4380 to Met4380 change, in nine of the 14 clones. We are examining whether this substitution is a normal polymorphism ofthe apo(a) gene or an amplification artifact. This result suggests that coamplification of the apo(a) gene corresponding to exon 16 of the PLG gene was performed with a set of specific primers for the PLG gene. Second, when exons 3,4, and 5 were independently subjected to sequence analysis, in each exon approximately two thirds of clones selected had normal PLG sequences. However, three different base changes and an in-frame stop codon, three different base changes, and a 14-nucleotide deletion in exons 3, 4, and 5, respectively, were detected in the remaining clones selected. These base changes in exons 3,4, and 5 are consistent with the sequence data of PLG related genes (PRG) reported by I~hinose,'~ indicating that the PRG genes corresponding to exons 3,4, and 5 of the PLG gene were also coamplified with a set of specific primers for the PLG gene. Third, a conservative C to T substitution at Cys238 codon (TGC) in exon 7 and an A to G substitution at Asn453 codon (AAT) (numbering according to Petersen et al') in exon 1 1, which results in an Asn453 to Asp453 (GAT) change, were also detected, which are consistent with normal polymorphic sites of the PLG gene reported by Ichinose et a124 and Forsgren et aL9
Genetic characterization with restriction enzyme digestion. To confirm that this substitution was present in the genomic DNA of the propositus and was not the consequence of Taq polymerase infidelity, we took advantage of the creation of a recognition site for the restriction enzyme Fok I (GGATG) in the PCR amplification product. As shown in Fig 2A, the normal PCR product of exon 14 predictably generates a 23 1 -bp fragment containing no Fok I recognition site, whereas the described mutation creates one Fok I site, resulting in two fragments ( 130 and 10 1 bp) after Fok I digestion. As predicted, the propositus (111-2 in Fig  2B) exhibited a composite digestion pattern compatible with one allele containing the identified missense mutation and another allele without this mutation.
To confirm further that the genetic basis for the phenouse only. type in this family is the described defect in exon 14 of the PLG gene, we applied the same strategy to other available members of the propositus' family. The mother (11-2) and one daughter (IV-3) of the propositus, in whom both the activity and antigen levels of PLG had been demonstrated to be approximately one half of the normal values by hemostatic analysis, also exhibited an identical pattern to that of the propositus after Fok I digestion and agarose gel electrophoresis. The younger sister (111-3), the son (IV-2), and the propositus' husband (11-4), all of whom had normal PLG activities and antigen levels, exhibited a pattern identical to that seen in amplified normal DNA. These results indicate use only. 
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Normal ' G A T C that a T to C transition in exon 14 identified in the propositus is responsible for the deficiency of PLG inherited in family N.
To eliminate the possibility that the described mutation in the propositus and her family is a common polymorphism, we digested with Fok I the amplified PCR fragments of exon 14 from 15 normal individuals. Only a 23 I-bp fragment-and not the 101-and 130-bp fragments observed in the propositus-was detected in these normal individuals (data not shown), suggesting that the described mutation is not common and is closely related to the PLG deficiency in family N.
DISCUSSION
Using a PCR strategy and restriction fragment polymorphism analysis, this study provides evidence that the inherited PLG deficiency in family N is the consequence of a missense mutation detected in exon 14 ofthe PLG gene. To our knowledge, this mutation is the first reported genetic abnormality in patients with congenital PLG deficiency.
To elucidate the genetic basis for PLG deficiency, we used a PCR strategy in which all 19 exons, including the exon-intron boundaries, were individually amplified with 19 sets of primers followed by subcloning into a M 13 vector and single-stranded DNA sequencing. It may be argued that this strategy is laborious and time-consuming; however, since a PRG gene is reported to be approximately 95% identical at the DNA level to a region from the Send ofthe PLG gene to intron E," and since the protease domain ofthe apo(a) gene also is 94% identical to that of PLG gene,12 we used this straightforward strategy rather than other screening methods for detecting mutations such as single-strand conformation polymorphism or denaturing gradient gel electrophoresis ana1y~es.I~ Indeed, when each exon of the PLG gene was amplified with a set of specific primers, the predicted-size PCR products were obtained in all cases, coamplification of the PRG and apo(a) genes corresponding to exons I , 3,4,5, 13, 16, and I7 of the PLG gene were performed, and some base changes in the PRG and apo(a) genes were shown by DNA sequencing. substitution in mature PLG molecules elicits the phenotype seen in the propositus have not yet been defined. However, available protein-sequence data show that PLG has strong homology to other serine proteases, such as chymotrypsinogen, trypsinogen I, pancreatic elastase 2, prothrombin, tPA, and protein C, in this region, and that a residue in
The mechanisms by which the Se$72 to use only. PLG is conserved among all of these proteins. Accordingly, the most probable explanation is that the mutation occurred within the activation cleavage region between the kringle domain and the serine protease domain on the PLG molecule. This may disrupt the protein's conformation and result in the impaired secretion of the mutant protein. In most, if not all, patients with congenital deficiency of plasma proteins, this mechanism has been shown by genetic engineering techniques to cause the disease."-" Transfection experiments in mammalian cells with plasmids containing normal or mutant PLG cDNA can be used to answer this question. Alternatively, the mutant PLG molecules, if they are secreted, may be cleared faster and more selectively than the normal molecules in the circulation. A case similar to ours has been described in a patient with ATIII deficiency, in whom the activity and antigen level of ATIII decreased to 60% and 40%, respectively, and DNA analysis showed a T to C substitution resulting in a 3'
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S e P 9 to Pro"' change." Although the authors have not characterized the behavior of the mutant ATIII molecules by biochemical studies with expressed recombinant molecules, Lane et all9 documented that the confomational integrity of the ATIII molecule was disrupted by the described mutation and a cryptic site on the mutant molecule was exposed without complex formation with a physiologic protease, thrombin. Consequently, the mutant molecules are cleared by hepatic receptors that specifically recognize ATIII-thrombin complexes. Gonzalez-Gronow et alZo showed that normal PLG molecules are cleared from the circulation mainly by binding to endothelial cells. In addition, they also reported that a fully glycosylated PLG molecule, PLG-I, cannot bind to endothelial cells, but a partially glycosylated PLG molecule, PLG-11, a nonglycosylated PLG molecule expressed in E coli and plasmin, can bind to these cells and be cleared faster than PLG-I in mice. This suggests that a receptor-recognition site on the PLG moleuse only.
For personal at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From cule is masked and can be exposed by conformational changes2' The discrepancy between the activity and antigen levels of PLG of the propositus in family N is not remarkably different from those of a patient with ATIII deficiency, although further biochemical and metabolical analyses with recombinant molecules are required to verify this hypothesis.
The detection of carriers in family N by conventional hemostatic and PCR-based restriction fragment polymorphism analyses confirmed that the propositus' allele, which produces the to Pro"2 mutant PLG molecules, was inherited from her mother, and that her husband was not a carrier of this mutation. One daughter of the propositus (IV-3 in Fig 2B) was a heterozygote who inherited a defective allele from the propositus, while her son (IV-2) carried two normal alleles. The genotype of another daughter (IVl), whose genomic DNA was not available, should consist of two normal alleles. It should be pointed out that these genetic analyses were in good agreement with the data of the PLG activity and antigen level in each member of family N. Therefore, the genetic information obtained in this study may be useful for carrier state detection at least in family N of individuals who may have low PLG activity due to liver disorders,22 of pregnant women in whom PLG activities are elevated due to hormonal changes,23 or of fetuses. Once identified, these individuals might benefit from appropriate treatment such as supplement therapy by a PLG-enriched agent. In addition, since the only point mutations identified thus far in 12 Japanese families with congenital dysplasminogenemia lie in only two codons,24 it may be possible to elucidate the genetic abnormalities in other patients with congenital PLG deficiency.
In conclusion, we identified the genetic abnormality in a Japanese family with congenital PLG deficiency. This is the first report in which a mutation causing familial congenital PLG deficiency was identified.
